Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date † | December 3, 2006 | ||||
Last Updated Date | January 26, 2009 | ||||
Start Date † | July 2006 | ||||
Current Primary Outcome Measures † | |||||
Original Primary Outcome Measures † | |||||
Change History | Complete list of historical versions of study NCT00456937 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures † | |||||
Original Secondary Outcome Measures † | |||||
Descriptive Information | |||||
Brief Title † | Escitalopram in Schizophrenia in OCD- Open Label Study | ||||
Official Title † | Escitalopram in the Treatment of Patient Suffering From Scizophrenia and Obsessive Compulsive Disorder- an Open Label Study | ||||
Brief Summary | SSRI's has been demonstrated to be partially effective in schizophrenia and OCD. We therefore suggest that Escitalopram up to 20 mg /d in those patients could be effective in reducing obsessive compulsive symptomatology |
||||
Detailed Description | |||||
Study Phase | Phase IV | ||||
Study Type † | Interventional | ||||
Study Design † | Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study | ||||
Condition † | Schizophrenia | ||||
Intervention † | Drug: Escitalopram | ||||
Study Arms / Comparison Groups | |||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status † | Completed | ||||
Estimated Enrollment † | 15 | ||||
Completion Date | September 2008 | ||||
Primary Completion Date | September 2008 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 18 Years to 65 Years | ||||
Accepts Healthy Volunteers | No | ||||
Contacts †† | |||||
Location Countries † | Israel | ||||
Expanded Access Status | |||||
Administrative Information | |||||
NCT ID † | NCT00456937 | ||||
Responsible Party | Dr Rafael Stryjer, Beer-Yaakov MHC | ||||
Secondary IDs †† | |||||
Study Sponsor † | BeerYaakov Mental Health Center | ||||
Collaborators †† | Lundbeck Israel | ||||
Investigators † |
|
||||
Information Provided By | BeerYaakov Mental Health Center | ||||
Verification Date | January 2009 | ||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |